itolizumab

03/01/2015 - "Itolizumab could be therefore an important treatment option for moderate to severe psoriasis, with potential to provide long-lasting remission."
03/01/2015 - "Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience."
01/01/2015 - "Based on the available published data, Itolizumab seems to have a better adverse effects profile and at the same time comparatively less efficacy when compared to other biological agents available for treating psoriasis. "
07/01/2017 - "Itolizumab is a safe and effective option in treatment-compliant patients with chronic plaque psoriasis. "
11/01/2016 - "Itolizumab was found effective and safe in the treatment of moderate to severe psoriasis patients."

10/01/2022 - "The aim of the study is to evaluate the effect of itolizumab on clinical outcomes of patients with moderate-severe COVID-19 disease admitted to ICU. "
01/01/2021 - "A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19."
01/01/2020 - "The primary objective of this study was to assess the impact of itolizumab in arresting the lung function deterioration of COVID-19 patients. "
01/01/2023 - "Itolizumab demonstrated acceptable safety with a favorable prognosis in hospitalized COVID-19 patients. "
10/01/2022 - "Role of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospital."

01/01/2016 - "Immunological evaluation of rheumatoid arthritis patients treated with itolizumab."
01/01/2016 - "Overall, the conducted clinical studies have demonstrated that itolizumab has favorable clinical effects and a safety profile when used as monotherapy in patients with rheumatoid arthritis and psoriasis. "
01/01/2018 - "The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial."
04/01/2016 - "The objective of this study was to assess the safety and efficacy of itolizumab with methotrexate in active rheumatoid arthritis (RA) patients who had inadequate response to methotrexate. "
01/01/2012 - "The purpose of this study was to evaluate the safety, immunogenicity and preliminary efficacy of itolizumab, a humanized anti-CD6 monoclonal antibody, in patients with active rheumatoid arthritis. "

01/01/2023 - "REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT."
04/01/2021 - "Here, we shared our clinical experience of 20 patients having moderate acute respiratory distress syndrome (ARDS) due to COVID-19 on treatment with itolizumab. "
12/01/2020 - "Based on the results, the Indian drug regulatory agency recently approved itolizumab in July 2020 for 'restricted emergency use' for the treatment of CRS in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. "
04/01/2021 - "Another Cuban product, itolizumab, is showing positive results mitigating cytokine release syndrome (CRS) in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). "
02/01/2021 - "Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study."

01/01/2016 - "This article provides an overview of the clinical data obtained in Cuban patients with autoimmune diseases who have been treated with IOR-T1 mAb or itolizumab. "
01/01/2016 - "Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab."
10/01/2018 - "CD6 monoclonal antibodies (mAbs) specific for the membrane distal domain (domain 1) perturb CD6 function including itolizumab (Alzumab™), which has reached the clinic for treatment of autoimmune disease. "
07/01/2013 - "Itolizumab has been proposed to be effective in autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis. "
01/01/2016 - "Hence, itolizumab represents a new therapeutic option for autoimmune diseases such as rheumatoid arthritis and psoriasis. "